SETD2 and chronic kidney disease: However, relative to the CKD group, SQJZ treatment markedly reduced their expression levels (p  < 0.05; Figure 5A), suggesting CHAC1 and HIF-1 α may serve as critical targets for SQJZ to exert its therapeutic effects.